ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH

NCT05478226 | Completed

• 1 other identifier: 2019XMSB000726
• Study Type: observational
• Target: 67
• Locations: 1 country
• Sites: 1

Brief Summary

ADAMTSL4 (A disintegrin and metalloproteinase with thrombospondin motifs like) is a member of the ADAMTSL family. ADAMTSL4 is one of the family of 7 ADAMTS-Like proteins, themselves part of the Thrombospondin type 1 repeat (TSR) superfamily of proteins. These 7 proteins are divided into two distinct clades, of which ADAMTSL4 and ADAMTS-Like 6 form part of one clade, differing from ADAMTS-Like 1, ADAMTS-Like 3 and ADAMTS-Like 7 by lacking immunoglobulin repeat regions. ADAMTSL4 is widely expressed in brain, colon, heart, kidney, liver, lung, pancreas and spleen, yet, its precise role is unclear. in addition, ADAMTSL4 protein high expression to the medial layer of the arterial wall, and medial vascular smooth muscle cells specifically.

Conditions

Pulmonary Hypertension

Outcome Measures

Primary Outcomes (1)

• Association of clinic index and ADAMTSL4 expression level

  The expression and its clinical relevance of ADAMTSL4 expression level in plasma or pulmonary tissue in patients with IPAH and CTEPH

  2018-2022

Study Arms (4)

control group

healthy people as control group

IPAH group

patients with IPAH as IPAH group

Other: drugs or BPA

CTEPH group

patients with CTEPH as CTEPH group

Other: drugs or BPA

group D

Including CTEPH group and IPAH group

Other: drugs or BPA

Interventions

drugs or BPA OTHER

PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat

CTEPH group; IPAH group; group D

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with IPAH and CTEPH compliance with 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

You may qualify if:

• \- Healthy people，patients with IPAH，patients with CTEPH

You may not qualify if:

• \- tumour，infection，Pregnancy, suckling period， Mental disorders，
• Other types of PAH except CTEPH and IPAH

Sponsors & Collaborators

• Wei Huang: lead

Study Sites (1)

the First Affiliated Hospital, Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood

MeSH Terms

Conditions

Hypertension, Pulmonary

Interventions

Pharmaceutical Preparations

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Wei Huang, Phd

  First Affiliated Hospital of Chongqing Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 26, 2022
• First Posted: July 28, 2022
• Study Start: July 1, 2018
• Primary Completion: August 31, 2020
• Study Completion: July 1, 2022
• Last Updated: July 28, 2022

Record last verified: 2022-07

Locations

CN (1)